Drug Trial Radar · NCT06058793
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Dec 13, 2023
Primary completion
Dec 12, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size.
Conditions
- Liposarcoma, Dedifferentiated
Interventions
BrigimadlinDrug
Brigimadlin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-emergent adverse events (TEAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 during the entire treatment periodTime frame: up to 23 months
- Occurrence of TEAEs with Grade ≥3 according to CTCAE version 5 during the entire treatment periodTime frame: up to 23 months
Locations
56 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic-Arizona
Phoenix, Arizona
Precision NextGen Oncology
Beverly Hills, California
Sarcoma Oncology Center
Santa Monica, California
University of California Los Angeles
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic - Florida
Jacksonville, Florida
University Cancer and Blood Center
Athens, Georgia
Northwestern University
Chicago, Illinois
University of Kansas Cancer Center
Overland Park, Kansas
Mayo Clinic, Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
John Theurer Cancer Center
Hackensack, New Jersey
Northwell Health
Lake Success, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania
West Cancer Center & Research Institute
Germantown, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists Cancer Center
Salt Lake City, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists, PC
Fairfax, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical Oncology Associates, P.S.
Spokane, Washington
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin
Hospital Britanico de Buenos Aires
CABA, Argentina
Sanatorio Finochietto
CABA, Argentina
Hospital Italiano de Buenos Aires
CABA, Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma de Bs As, Argentina
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Pronutrir
Fortaleza, Brazil
Hospital do Cancer de Londrina
Londrina, Brazil
CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
Santo André, Brazil
Hospital Sao Domingos
São Luís, Brazil
H.S.J. Beneficência Portuguesa - São Paulo
São Paulo, Brazil
Arthur J. E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.